US approves first at-home cervical cancer screening device
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
17 May 2025 05:00pm
This undated handout image obtained on May 9, 2025, courtesy of Teal Health, shows the Teal Wand, an at-home cervical cancer screening device approved by the FDA. (Photo by Nicole Morrison/Teal Health/AFP)
WASHINGTON - The US Food and Drug Administration has approved an at-home cervical cancer screening tool as an alternative to Pap smears by a gynecologist, the company behind the device said recently.
The "Teal Wand" -- a self-collection vaginal swab shaped like a tampon and developed by Teal Health -- will be available online for individuals aged 25 to 65 who are at average risk for cervical cancer.
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
Cervical cancer, which affects the lower part of the uterus, is diagnosed in about 0.6 percent of women. Although HPV vaccination and regular screening are highly effective at preventing the disease, more than one in four women fall behind on routine appointments.
"When we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day," Teal Health CEO Kara Egan said in a statement.
The Teal Wand tests for high-risk strains of human papillomavirus (HPV), the primary cause of cervical cancer.
A large clinical trial found its accuracy comparable to a traditional Pap smear, which requires a speculum and is often cited as a barrier to screening due to discomfort.
Most sexually active people will contract HPV at some point, though only a small fraction develop cancer.
Teal Health did not disclose pricing but said it is in talks with insurers to ensure affordability. The product will launch first in California in June. - AFP
More Like This
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
7 hours ago
- The Star
Man who let snakes bite him 200 times spurs new antivenom hope
SOUTH-EAST ASIA/PARIS (AFP): Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization. These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. - 'Pain every time' - Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. Researchers hope Friede's hyper-immunity could even lead to the development of a universal anti-venom. -- PHOTO: AFP However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. - 'Proud' - For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said. - AFP
New Straits Times
14 hours ago
- New Straits Times
Man who let snakes bite him 200 times spurs new antivenom hope
TIM Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization. These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. However this antivenom usually only works for bites from that particular species of snake – and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes – particularly vipers – with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. * The writer is from AFP Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said.
Borneo Post
20 hours ago
- Borneo Post
China's homegrown 9-valent HPV vaccine expected to boost immunisation coverage
A girl receives a human papillomavirus (HPV) vaccine at the provincial Maternity and Child Healthcare Hospital in Wuhan, central China's Hubei Province, May 18, 2020. – Xinhua photo BEIJING (June 8): China's drug regulator has approved the country's first domestically developed 9-valent human papillomavirus (HPV) vaccine, ending over a decade of foreign dominance in the market. The vaccine, Cecolin 9, has been included on a list of approved medical products that was made public by the National Medical Products Administration on Wednesday. 'The approval of Cecolin 9 not only offers more vaccination options for eligible women in China, but is also expected to improve vaccine accessibility and coverage, reducing the risk of cervical cancer further,' said Zhang Jun, dean of the School of Public Health at Xiamen University and a leading member of the vaccine development team. HPV vaccines are commonly used to prevent cervical cancer in women, as well as genital cancers and warts in both men and women. Cecolin 9, which targets nine HPV strains, was developed by Xiamen University, the Xiang An Biomedicine Laboratory and Xiamen Innovax Biotech Co., Ltd, marking a breakthrough in China's ability to produce high-valency HPV vaccines independently. China is now the second country – after the United States – capable of supplying 9-valent HPV vaccines. Compared to bivalent HPV vaccines, which are effective against two high-risk genotypes (HPV 16 and 18), 9-valent HPV vaccines protect against an additional five high-risk genotypes (HPV 31, 33, 45, 52 and 58) and two low-risk genotypes (HPV 6 and 11), and provide better protection against cervical cancer. Over 18 years of research, scientists overcame major technical challenges in producing virus-like particles (VLPs) from multiple HPV types using an E. coli platform, and completed crucial clinical trial validation processes. Five related clinical trials have been conducted across China since 2019, and the vaccine has demonstrated a favorable safety profile and a strong immune response, comparable to those of similar international products. Statistics show that globally, approximately 700,000 cancer cases each year are associated with HPV, including an estimated 530,000 cases of cervical cancer. Vaccination is up to 94 percent effective in preventing HPV infection. In 2020, the World Health Organisation (WHO) launched a global strategy to accelerate the elimination of cervical cancer, aiming for 90 percent of girls to be fully vaccinated against HPV by the age of 15 by 2030. In alignment with the WHO strategy, China's National Health Commission launched a cervical cancer elimination action plan for the 2022-2030 period, urging the expansion of HPV vaccination coverage nationwide. 9-valent human papillomavirus China hpv vaccine
